News from the healthcare data industry
When Robert Califf became the new commissioner of the U.S. Food & Drug Administration, he did so with a plan to emphasize the use of real-world evidence (RWE) in Agency decisions....
Findings highlight the unmet medical need among cancer patients with BRAF Class II and Class III alterations who may not have access to approved targeted therapies SAN FRANCISCO and SAN...
Company expands its offerings with a mission to organize digital health products that enable patients and their providers to make objective, data-driven decisions about their healthcare March 07, 2022 07:00...
The new investment will accelerate Health Gorilla’s mission to connect everyone, everywhere, with actionable health data. Palo Alto, California, March 07, 2022 (GLOBE NEWSWIRE) — Health Gorilla, a leading Health Information...
Background To assess the performance of various coding algorithms for identifying people with hepatitis B virus (HBV) and hepatitis C virus (HCV) using claims data according to different reference standards...
New partnership allows for a 40,000+ patient dataset to unlock new insights into cancer treatments and outcomes.xCures and BioSpark are driving a fundamental shift in the quality, utility, and value...
SAN FRANCISCO, March 3, 2022 /PRNewswire/ — NephroSant™ a biotechnology company dedicated to accelerating the diagnosis of early kidney damage in native and transplanted kidneys, with a mission to significantly improve global kidney...
Abstract The landscape for evidence generation in hematologic malignancies is rapidly evolving. While randomized controlled trials (RCTs) remain the gold standard in support of drug efficacy, approval and use, the...
“Hotspot mapping” accelerates early-phase drug design CCDC, Exscientia, and Oxford University collaborate on an automated, quantitative method for informing the design of compound selectivity across protein families Cambridge Crystallographic Data...
Posted 02 March 2022 | By Mary Ellen Schneider Pharmaceutical manufacturers and patient advocates want to see more details from the US Food and Drug Administration as it finalizes guidance on...